Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Intech Biopharm's enterprise value is NT$2,923.23 Mil.
Intech Biopharm's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-357.40 Mil. Therefore, Intech Biopharm's EV-to-EBITDA for today is -8.18.
The historical rank and industry rank for Intech Biopharm's EV-to-EBITDA or its related term are showing as below:
ROCO:6461'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -116.94 Med: -17.74 Max: -7.42
Current: -8.18
During the past 13 years, the highest EV-to-EBITDA of Intech Biopharm was -7.42. The lowest was -116.94. And the median was -17.74.
ROCO:6461's EV-to-EBITDA is ranked worse than 100% of 404
companies
in the Biotechnology industry
Industry Median: 13.02
vs ROCO:6461: -8.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Intech Biopharm's PE Ratio (TTM) for today is calculated as:
Intech Biopharm's share price for today is NT$25.50.
Intech Biopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Intech Biopharm's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6461 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Intech Biopharm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intech Biopharm EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intech Biopharm's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Intech Biopharm's EV-to-EBITDA falls into.
Intech Biopharm's current Enterprise Value is NT$2,923.23 Mil.
Intech Biopharm's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-357.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intech Biopharm (ROCO:6461) has a EV-to-EBITDA of -8.18 as of Sep. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Intech Biopharm. According to the industry distribution chart, Intech Biopharm ranks #999999 out of 404 companies in the Biotechnology industry.
Is Intech Biopharm's EV-to-EBITDA too high?
Intech Biopharm's current EV-to-EBITDA is -8.18. Based on the distribution chart, Intech Biopharm ranks #999999 out of 404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Intech Biopharm has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intech Biopharm ranks #999999 out of 404 companies for EV-to-EBITDA. This places Intech Biopharm in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Intech Biopharm. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intech Biopharm's current EV-to-EBITDA is -8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$42.25, compared to a current price of NT$25.50 — trading 39.6% below its estimated fair value. The current EV-to-EBITDA is -8.18. Intech Biopharm's overall GF Score™ is 59/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current EV-to-EBITDA is -8.18 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intech Biopharm (ROCO:6461) Overvalued in 2026?
Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued.
The current stock price of NT$25.50 is trading 39.6% below its estimated GF Value™ of NT$42.25.
GuruFocus considers Intech Biopharm to be Possible Value Trap.
Key valuation signals for ROCO:6461:
EV-to-EBITDA: -8.18
GF Value™: NT$42.25 vs. price of NT$25.50 (39.6% below fair value)
No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
59GF Score
Get the complete analysis for ROCO:6461
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6461 has been successfully added to your 
